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P yoderma gangrenosum (PG) is a rare inflammatory skincondition with an estimated incidence of 3 to 10 cases permillion people per year. It was first described in 1908 as a
“geometric phagedena” (phagédénisme géométrique)1 and was
later redefined as PG in 1930.2 Multiple variants of PG exist, but
ulcerative PG typically presents as tender papules or pustules that
evolve into painful and rapidly expanding ulcers. Initially thought
to be of infectious etiology, the pathogenesis of PG is still not well
understood. Currently, most consider PG to be a prototypic neu-
trophilic dermatosis, possibly driven by an autoinflammatory
process.3
Diagnosis of PG has been challenging owing to its variable pre-
sentation, clinical overlap with other conditions, association with
several systemic diseases, and absence of defining histopathologic
or laboratory findings. For example, ulcerations may be seen in
other neutrophilic disorders, vascular disorders, malignancy, and
infections. Although the histopathology of PG typically shows
neutrophilic inflammation, this manifestation is nonspecific and
may vary based on PG subtype, ulcer stage, and timing of biopsy.
Misdiagnosis and delayed diagnosis are common; in 1 retrospec-
tive study,4 39% of patients who initially received a diagnosis of
PG were ultimately found to have an alternative diagnosis. Impor-
tantly, misdiagnosis may present substantial risks to patients
because some PG treatments are contraindicated in cases of
active infection or malignancy.
There are currently no uniformly accepted diagnostic criteria
for PG. Previously published criteria by Su et al5 maintain ulcer-
ative PG as a diagnosis of exclusion, which may be impractical and
impede diagnosis. Also, to our knowledge, there have been no
publications using a systematic approach to develop diagnostic
criteria for PG. This lack of structure in approaching diagnosis
makes patient selection for clinical trials particularly difficult and
IMPORTANCE Pyoderma gangrenosum is a rare inflammatory skin condition that is difficult to
diagnose. Currently, it is a “diagnosis of exclusion,” a definition not compatible with clinical
decisionmaking or inclusion for clinical trials.
OBJECTIVE To propose and validate diagnostic criteria for ulcerative pyoderma gangrenosum.
EVIDENCE REVIEW Diagnostic criteria were created following a Delphi consensus exercise
using the RAND/UCLA Appropriateness Method. The criteria were validated against
peer-reviewed established cases of pyoderma gangrenosum andmimickers using k-fold
cross-validation with methods of multiple imputation.
FINDINGS Delphi exercise yielded 1 major criterion—biopsy of ulcer edge demonstrating
neutrophilic infiltrate—and 8minor criteria: (1) exclusion of infection; (2) pathergy; (3) history
of inflammatory bowel disease or inflammatory arthritis; (4) history of papule, pustule, or
vesicle ulcerating within 4 days of appearing; (5) peripheral erythema, undermining border,
and tenderness at ulceration site; (6) multiple ulcerations, at least 1 on an anterior lower leg;
(7) cribriform or “wrinkled paper” scar(s) at healed ulcer sites; and (8) decreased ulcer size
within 1 month of initiating immunosuppressive medication(s). Receiver operating
characteristic analysis revealed that 4 of 8minor criteria maximized discrimination, yielding
sensitivity and specificity of 86% and 90%, respectively.
CONCLUSIONS AND RELEVANCE This Delphi exercise produced 1 major criterion and 8minor
criteria for the diagnosis of ulcerative pyoderma gangrenosum. The criteria may serve as a
guideline for clinicians, allowing for fewer misdiagnoses and improved patient selection for
clinical trials.
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prone tomisclassification. For example, in the largest of the 2 clini-
cal trials conducted to date, clinical PG diagnosis in 9 of 121 partici-
pants was later revised after randomization.6 To bridge this clinical
gap, we assembled a set of diagnostic criteria for ulcerative PG
using the Delphi method following the RAND/UCLA Appropriate-
ness Method7 and subsequently validated the criteria against
published cases of PG and its mimickers.
Methods
Panel Selection
Panel members were selected based on first or last authorship on
PG publications in high-impact medical journals, as identified
through the Web of Science using the search term pyoderma
gangrenosum, in August 2015. Case reports and minor publica-
tions were not considered. In addition, participating physicians
were allowed to recommend other PG experts for the panel.7 This
process yielded 15 physicians representing 6 countries and
10 universities. Three physicians did not respond to the invitation,
and the remaining 12 agreed to participate.
Delphi Exercise
First Round
In the first round of the Delphi exercise, the participating
12 committee members were sent an online survey consisting
of 21 statements regarding the diagnosis of PG. The panel evalu-
ated the level of appropriateness of statements in relation to PG
on a scale of 1 (extremely inappropriate) to 9 (extremely appropri-
ate). Participants were given the option of selecting “N/A” if they
felt they did not have the necessary expertise to rank a particular
statement. Statements presented for criteria were assembled
from Scopus andWeb of Science literature searches of highly cited
manuscripts about PG and included prior suggested diagnostic
criteria.4,5,8,9 The search was conducted in August 2015 using the
term pyoderma gangrenosum. Results were deidentified prior to
releasing them to the panel, and participants were able to suggest
new statements.
Statistics
Results were analyzed using the RAND/UCLA Appropriateness
Method.7 For each statement, the median rating for appropriate-
ness, interpercentile range (IPR), interpercentile range adjusted
for symmetry (IPRAS), and disagreement index (DI) were calcu-
lated (DI = IPR/IPRAS).7 A median rating of 1.0 to 3.4 was consid-
ered to be “inappropriate,” 3.5 to 6.9 to be “uncertain,” and 7.0 to
9.0 to be “appropriate.” A (DI) value greater than or equal to
1 (DI  1) indicated a lack of consensus among the participants
regarding the appropriateness of the statement. For further
details, please see eAppendix 1 in the Supplement.
Second and Third Rounds
During the second and third rounds, participants ranked new
suggested statements and revised statements that failed the
previous rounds.
Fourth Round
Statements that were agreed on (DI < 1) to be appropriate were
used to develop a set of diagnostic criteria for PG (Figure 1). State-
ments that the panel agreed to be required for diagnosis were des-
ignated as major criteria, whereas those that were deemed to be
helpful but not required were designated as minor criteria. The
panel was asked to rate the appropriateness or usefulness of the
new criteria using the same scale.
Validation
Case reports of ulcerative PG and mimickers were collected
through a PubMed search for cases published in respected peer-
reviewed medical journals chosen by impact factor (Journal of the
American Academy of Dermatology, JAMA Dermatology, British
Journal of Dermatology, Journal of the European Academy of
Dermatology and Venereology, and Acta Dermato-Venereologica)
from 2001 to 2016.10-47 To balance the number of PG cases and
mimics, additional cases of non-PG ulcers were found using the
search terms ulcer and vasculitis, ulcer and venous, and ulcer and
calciphylaxis because such ulcers are often misdiagnosed as
PG (eAppendix 2 in the Supplement).4 Case series were excluded
if they contained grouped data and lacked patient-specific
details. When necessary, corresponding authors were contacted
in an attempt to recover diagnostic information missing from
the publications.
Subsequently, the data from the case reports underwent
multiple imputation to address data missing from the case reports
using the missing at random and missing completely at random
Figure 1.Diagnostic Criteria for ClassicUlcerativePyodermaGangrenosum
Biopsy of ulcer edge demonstrating 
a neutrophilic infiltrate
Histology
 Exclusion of infectiona
History
 Pathergy (ulcer occurring at sites
 of trauma)b
 Personal history of inflammatory
 bowel disease or inflammatory
 arthritis
 History of papule, pustule, or
 vesicle that rapidly ulcerated
Clinical examination (or photographic
 evidence)
 Peripheral erythema,
 undermining border, and tenderness
 at site of ulceration
 Multiple ulcerations (at least 1
 occurring on an anterior lower leg)
 Cribriform or “wrinkled paper”
 scar(s) at sites of healed ulcers
Treatment
 Decrease in ulcer size within
 1 mo of initiating
 immunosuppressive
 medication(s)
Consider rebiopsy if ulcer does
not resolve or if patient
develops a new lesion
Diagnostic criteria for classic ulcerative pyoderma gangrenosum
No
Yes
In addition to a biopsy demonstrating a neutrophilic infiltrate, patients must
have at least 4minor criteria to meet diagnostic criteria.
a Including histologically indicated stains and tissue cultures.
bUlcer should extend past area of trauma.
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assumptions. Diagnostic model performance was evaluated by
calculating the area under the receiver operating characteristic
curve (AUC) and validated by k-fold cross-validation (Figure 2).
For details on these statistical analyses, see eAppendix 3 in
the Supplement.
Results
Delphi Exercise
All 12 physicians responded to every round of the Delphi exercise
(100% response rate). The results of the first 3 rounds are tabu-
lated in eAppendix 4 in the Supplement.
Afterward, the statements that the panel “agreed” were
“appropriate” were used to develop a total of 9 criteria (1 major
criterion and 8 minor criteria) for the diagnosis of ulcerative PG.
The panel then subsequently “agreed” (DI = 0.22) that the final
criteria were “appropriate or useful” (median rating of 7).
Diagnostic Criteria
During the first round of the Delphi exercise, biopsy was
proposed as a minor criterion, but the panel could not agree
on the appropriateness of this statement (DI = 1.3). Instead,
they agreed that a biopsy should be required in diagnosing PG.
Thus, biopsy was made into a major criterion and is the first
step of our diagnostic criteria. Importantly, a biopsy at the ulcer
edge was agreed to be superior to a biopsy made at an alternative
ulcer site.
In addition, the panel strongly agreed that histologic features
seen in PG included dermal edema with neutrophilic inflamma-
tion. Absence of infection was deemed helpful but not required in
diagnosing PG. Biopsy demonstrating leukocytoclastic vasculitis
was not thought to exclude a diagnosis of PG because this finding
can be seen in PG lesions.48
While the rate of ulcer progression and the presence of an
undermining border were considered major criteria for ulcerative
PG per Su et al,5 these features were deemed to be helpful but not
required by our expert panel, and thus they were designated as
minor criteria. Other clinical findings that the panel agreed were
helpful but not required included peripheral erythema and pain
at the ulcer site.
With regard to patient history, pathergy has been described
as an important trigger for PG, with 20% to 30% of PG cases
reportedly occurring after minor trauma.49 The panel was in
agreement that pathergy was helpful but not required for PG
diagnosis. History of an inflammatory papule, pustule, or vesicle
that rapidly ulcerates was also thought to be helpful. The panel
also agreed that history of inflammatory bowel disease or inflam-
matory arthritis would assist in diagnosis, which is supported
by literature showing a strong association between these
2 conditions and PG.50
During the second round of the Delphi exercise, the panel
approved a newly introduced statement that decreased ulcer size
after immunosuppressive therapy is useful in diagnosing PG. The
panel also reached an agreement confirming that the diagnosis
may be supported by the presence of multiple ulcers, particularly
on the anterior legs. During the third round, the panel agreed that
either cribriform or wrinkled paper scarring may be useful in the
diagnosis of PG.
Agreed on items were then used to generate the proposed
diagnostic criteria for PG, which included 1 major criterion and 8
minor criteria. Some statements were revised based on patient
and expert panel comments. The set of criteria was then submit-
ted to the participants, who approved the new diagnostic criteria.
Validation
Our approved diagnostic criteria were then tested and validated
against 113 case reports. Of these, 65 pertained to PG and 48
Figure 2. Receiver Operating Characteristic (ROC) Curve From k-Fold Cross-Validation
Exclusion of infection (1)
Pathergy (2)
History of inflammatory bowel
disease or inflammatory
arthritis (3)
History of papule, pustule, or
vesicle ulcerating within 4 d 
of appearing (4)
Peripheral erythema,
undermining border, and
tenderness at ulceration site (5)
Multiple ulcerations, at least 1
on an anterior lower leg (6)
Cribriform or “wrinkled paper”
scars at healed ulcer sites (7)
Decreased ulcer size within 1 mo
of initiating immunosuppressive
medication(s) (8)
0
1.0
0.8
Tr
ue
-P
os
iti
ve
 R
at
e,
 S
en
si
tiv
ity
0.4
0.2
0 0.4 0.6 0.8 1.0
False-Positive Rate, 1 – Specificity
0.2
ROC curve using 1-8 minor criteriaA
0
1.0
0.8
Tr
ue
-P
os
iti
ve
 R
at
e,
 S
en
si
tiv
ity
0.4
0.2
0 0.4 0.6 0.8 1.0
False-Positive Rate, 1 – Specificity
0.2
ROC curve using 1 major criterion and 1-8 minor criteriaB
A, ROC curve using 1 to 8minor criteria as the threshold for diagnosis, in which
biopsy is designated as a minor criterion. B, ROC curve using 1 major and 1 to 8
minor criteria as the threshold for diagnosis, in which biopsy is designated as a
major criterion. Biopsy as a major criterion improved the performance of all
diagnostic models. The 8minor criteria are as follows: (1) exclusion of infection;
(2) pathergy; (3) history of inflammatory bowel disease or inflammatory
arthritis; (4) history of papule, pustule, or vesicle ulcerating within 4 days of
appearing; (5) peripheral erythema, undermining border, and tenderness at
ulceration site; (6) multiple ulcerations, with at least 1 on an anterior lower leg;
(7) cribriform or “wrinkled paper” scar(s) at healed ulcer sites; and
(8) decreased ulcer size within 1 month of initiating immunosuppressive
medication(s).
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pertained to PG mimickers. The frequency with which each crite-
rion is present in the cases is summarized in Table 1. k-Fold cross-
validation confirmed the use of biopsy as a major rather than
minor criterion because it increased the performance of all mod-
els. In addition, 5 minor criteria were determined to be optimal
under the missing at random assumption (AUC = 0.95, sensitiv-
ity = 80%, and specificity = 95%), 4 minor criteria were deter-
mined to be optimal under the missing completely at random
assumption (AUC = 0.93, sensitivity = 86%, and specific-
ity = 90%), and 3 minor criteria were determined to be optimal
under a single imputation (AUC = 0.92, sensitivity = 80%, and
specificity = 88%) (Table 2). Four minor criteria were ultimately
determined as the threshold for PG diagnosis given the optimal
combination of sensitivity and specificity and similar AUCs under
the missing at random and missing completely at random
assumptions compared with 5 minor criteria.
Discussion
Thisstudycalculatestheoptimaldiagnosticcriteriatomaximizediscrimi-
nation inulcerativePG,yieldingsensitivityandspecificityof86%and
90%,respectively. Inaddition,thisworkconsolidatestherelevantclini-
cal andhistopathologic findingsusing expert panel consensus.
The greatest benefit of these diagnostic criteria compared
with previous standards5 is that PG will no longer be a diagnosis of
exclusion. Instead, diagnosis rests on clinical history, presentation,
histopathology, and resolution pattern. Importantly, biopsy of the
ulcer edge must demonstrate a neutrophilic infiltrate to establish
the diagnosis of PG. However, the presence of a mixed infiltrate or
a diagnosis of leukocytoclastic vasculitis does not completely
exclude the possibility of PG. Exclusion of infection through histo-
logically indicated stains and tissue cultures aids in diagnosis but is
not required because superinfection is possible.22,46 Therefore,
exclusion of infection is best done through histology. Although
superficial wound cultures could be obtained on a case-by-case
basis, it is not part of our diagnostic criteria because it may overes-
timate bacterial colonization and superinfection while underesti-
mating slow-growing bacteria, fungus (eg, Sporothrix schenckii),
mycobacteria, and viruses. This emphasis on histopathology is
unlike previously suggested diagnostic approaches, which relied
predominantly on clinical features.5,8,9 Also, positive findings are
as useful as negative findings on biopsy in our diagnostic criteria.
Although the associationbetweenmalignancy andPGhasbeen
demonstrated in the literature,49malignancy history did not pass as
a minor criterion. However, some panel members felt strongly that
history of malignancy aids in PG diagnosis. Finally, it is important to
underscore that if biopsy is determined to show an alternative diag-
nosis by the pathologist, our diagnostic criteria need not be applied.
Our diagnostic criteria were validated against published PG
case reports. Case reports were used as the criterion standard
diagnosis because they receive higher scrutiny and peer review
prior to publication. However, a limitation of the data are the lim-
ited validation set. Additional validation testing in broader mimick-
ing populations may be valuable. A further limitation was that
some case reports did not contain sufficient information to use all
components of the criteria. We addressed this issue by contacting
corresponding authors for the missing information and by per-
forming statistical analyses that accounted for the missing data.
While these criteria have demonstrated high sensitivity and
specificity for the diagnosis of ulcerative PG, atypical casesmay be
missed—in particular, cases in which a biopsy was obtained after
initiationof immunosuppressivetherapyorduringspontaneousreso-
lution. Biopsies taken at such timepointsmay fail to demonstrate a
neutrophilic infiltrate. Thus, it is important to rebiopsy patients
during subsequent flares if diagnosis remains uncertain.
Our diagnostic criteria remove ulcerative PG as a diagnosis of
exclusion and will change how physicians approach this challeng-
ing disease. It will also allow formore accurate patient selection for
clinical trials.
Table 1. Presence of Criteria in 113 Case Reports and Statistical Significance UsingMAR andMNARAssumptions
Criteria
Case Reports, No. (%) Significancea
PG Cases Fulfilling
Criterion (n = 65)
Mimics Fulfilling
Criterion (n = 48)
Under MAR
Assumption
Under MNAR
Assumption
Biopsy with neutrophilic infiltrate 51 (78) 7 (15) 100 100
Exclusion of infection on histology 17 (26) 7 (15) 38 26
Pathergy 23 (35) 4 (8) 87 94
Personal history of IBD or inflammatory arthritis 15 (23) 9 (19) 0 0
Papule, pustule, or vesicle that rapidly ulcerates 27 (42) 0 95 72
Peripheral erythema, undermining border, and tenderness at site of ulceration 59 (91) 12 (25) 100 100
Multiple ulcerations (at least one occurring on an anterior lower leg) 36 (55) 20 (42) 3 0
Cribriform or wrinkled paper scars at healed ulcer sites 25 (38) 4 (8) 100 100
Decrease in ulcer size after immunosuppressive treatment 55 (85) 10 (21) 100 100
Abbreviations: IBD, inflammatory bowel disease; MAR, missing at random; MNAR, missing not at random; PG, pyoderma gangrenosum.
a Number of times predictor was statistically significant (P < .05) for the PGmodel.
Table 2. Performance of the BestModels UnderMAR,MNAR,
and Single Imputation Assumptions
Parameter MAR MNAR
Single
Imputation
Minor criteria, No. 5 4 3
Area under the curve,
mean (SD)
0.95 (0.02) 0.94 (0.02) 0.92 (0.02)
Sensitivity,
mean (SD), %
0.80 (0.04) 0.86 (0.06) 0.80 (0.05)
Specificity,
mean (SD), %
0.95 (0.03) 0.90 (0.03) 0.88 (0.05)
Abbreviations: MAR, missing at random; MNAR, missing not at random.
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Conclusions
Rather than maintain PG as a diagnosis of exclusion, this set
of criteria is unique and practical in its ability to diagnose PG
using clear major and minor criteria. Furthermore, the
diagnostic model of 1 major criterion and 4 of 8 minor criteria
as the threshold for diagnosis was validated, achieving high
sensitivity and specificity. We expect these criteria to gain
wide acceptance and serve as a guideline for clinicians,
al lowing for fewer misdiagnoses and improved patient
selection for clinical trials. Future research directions in this area
involve further clinical validation of the diagnostic criteria in
prospective studies.
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